Statistical Test/Estimation Methods Used in Contemporary Phase III Cancer Randomized Controlled Trials with Time-to-Event Outcomes-Reference-Cited by-同舟云学术

Statistical Test/Estimation Methods Used in Contemporary Phase III Cancer Randomized Controlled Trials with Time-to-Event Outcomes

Published:2019-11-19 Issue:2 Volume:25 Page:91-93
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Uno Hajime¹²,Horiguchi Miki¹,Hassett Michael J.¹

Affiliation:

1. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

2. Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Abstract

There exist a wide variety of statistical methods for clinical trials. Despite decades of clinical trial research, little is known about which methods are used in data analysis practice of the real world. This review describes the evidence of existing practices on survival data analysis and identifies potential opportunities to improve them.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.2019-0464

Reference14 articles.

1. Regression models and life-tables;Cox;J Royal Stat Soc Ser B Stat Methodol,1972

2. Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis;Uno;J Clin Oncol,2014

3. Alternatives to hazard ratios for comparing the efficacy or safety of therapies in noninferiority studies;Uno;Ann Intern Med,2015

4. How do the accrual pattern and follow-up duration affect the hazard ratio estimate when the proportional hazards assumption is violated?;Horiguchi;The Oncologist,2019

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Robust and Interpretable Hazard-based Summary Measures of the Magnitude of the Treatment Effect and Their Inference Procedures;Japanese Journal of Biometrics;2024-07-30

2. Biomarkers in Oncology: Complexities in Biomarker-Driven Studies and Statistical Analysis;JCO Precision Oncology;2024-07

3. Regression models for average hazard;Biometrics;2024-03-27

4. Designing superiority trials with window mean survival time as a primary endpoint;Statistics in Medicine;2023-03-31

5. On assessing survival benefit of immunotherapy using long‐term restricted mean survival time;Statistics in Medicine;2023-01-18